A detailed history of Erste Asset Management Gmb H transactions in Voyager Therapeutics, Inc. stock. As of the latest transaction made, Erste Asset Management Gmb H holds 1,058,378 shares of VYGR stock, worth $5.99 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
1,058,378
Holding current value
$5.99 Million
% of portfolio
0.07%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$5.77 - $9.27 $6.11 Million - $9.81 Million
1,058,378 New
1,058,378 $6.19 Billion
Q1 2022

Nov 22, 2024

BUY
$2.75 - $9.44 $715,000 - $2.45 Million
260,000 Added 27.0%
1,222,900 $9.36 Billion
Q4 2021

Nov 22, 2024

BUY
$2.47 - $5.55 $505,169 - $1.14 Million
204,522 Added 19.32%
1,262,900 $3.59 Billion
Q3 2021

Nov 22, 2024

BUY
$2.63 - $4.12 $578,600 - $906,400
220,000 Added 29.61%
962,900 $2.55 Billion
Q2 2021

Nov 22, 2024

BUY
$3.94 - $5.44 $591,000 - $816,000
150,000 Added 25.3%
742,900 $3.07 Billion
Q1 2021

Nov 22, 2024

BUY
$4.61 - $9.04 $945,050 - $1.85 Million
205,000 Added 52.85%
592,900 $2.81 Billion
Q4 2020

Nov 22, 2024

BUY
$7.15 - $12.28 $321,750 - $552,600
45,000 Added 13.12%
387,900 $2.82 Billion
Q3 2020

Nov 22, 2024

SELL
$10.01 - $13.75 $7.16 Million - $9.84 Million
-715,478 Reduced 67.6%
342,900 $3.68 Billion
Q2 2020

Nov 22, 2024

BUY
$8.05 - $14.21 $72,450 - $127,890
9,000 Added 2.7%
342,900 $4.3 Billion
Q1 2020

Nov 22, 2024

BUY
$6.8 - $14.66 $88,400 - $190,580
13,000 Added 4.05%
333,900 $3.03 Billion
Q4 2019

Nov 22, 2024

SELL
$12.82 - $16.85 $9.45 Million - $12.4 Million
-737,478 Reduced 69.68%
320,900 $4.33 Billion
Q3 2019

Nov 22, 2024

BUY
$16.31 - $28.29 $114,169 - $198,030
7,000 Added 2.34%
305,900 $5.26 Billion
Q1 2019

Nov 22, 2024

SELL
$8.0 - $19.66 $6.08 Million - $14.9 Million
-759,478 Reduced 71.76%
298,900 $5.71 Billion

Others Institutions Holding VYGR

About Voyager Therapeutics, Inc.


  • Ticker VYGR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,647,600
  • Market Cap $219M
  • Description
  • Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...
More about VYGR
Track This Portfolio

Track Erste Asset Management Gmb H Portfolio

Follow Erste Asset Management Gmb H and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Erste Asset Management Gmb H, based on Form 13F filings with the SEC.

News

Stay updated on Erste Asset Management Gmb H with notifications on news.